Market Research Logo

Gallbladder Cancer - Pipeline Review, H1 2018

Gallbladder Cancer - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H1 2018, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.

Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history, gallstones, gender and choledochal cysts. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gallbladder Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Gallbladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gallbladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 17, 5 and 2 respectively.

Gallbladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gallbladder Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gallbladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gallbladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gallbladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gallbladder Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gallbladder Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gallbladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Gallbladder Cancer - Overview
Gallbladder Cancer - Therapeutics Development
Gallbladder Cancer - Therapeutics Assessment
Gallbladder Cancer - Companies Involved in Therapeutics Development
Gallbladder Cancer - Drug Profiles
Gallbladder Cancer - Dormant Projects
Gallbladder Cancer - Discontinued Products
Appendix
List of Tables
Number of Products under Development for Gallbladder Cancer, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Gallbladder Cancer - Pipeline by 4SC AG, H1 2018
Gallbladder Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018
Gallbladder Cancer - Pipeline by Array BioPharma Inc, H1 2018
Gallbladder Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018
Gallbladder Cancer - Pipeline by Bayer AG, H1 2018
Gallbladder Cancer - Pipeline by BeiGene Ltd, H1 2018
Gallbladder Cancer - Pipeline by Eli Lilly and Co, H1 2018
Gallbladder Cancer - Pipeline by Halozyme Therapeutics Inc, H1 2018
Gallbladder Cancer - Pipeline by Hutchison MediPharma Ltd, H1 2018
Gallbladder Cancer - Pipeline by Ipsen SA, H1 2018
Gallbladder Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Gallbladder Cancer - Pipeline by Kringle Pharma Inc, H1 2018
Gallbladder Cancer - Pipeline by Leap Therapeutics Inc, H1 2018
Gallbladder Cancer - Pipeline by MedImmune LLC, H1 2018
Gallbladder Cancer - Pipeline by Molecular Templates Inc, H1 2018
Gallbladder Cancer - Pipeline by Novartis AG, H1 2018
Gallbladder Cancer - Pipeline by NuCana Plc, H1 2018
Gallbladder Cancer - Pipeline by OncoTherapy Science Inc, H1 2018
Gallbladder Cancer - Pipeline by Taris Biomedical LLC, H1 2018
Gallbladder Cancer - Pipeline by VasGene Therapeutics Inc, H1 2018
Gallbladder Cancer - Dormant Projects, H1 2018
Gallbladder Cancer - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Gallbladder Cancer, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report